ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1106

Plasma and Erythrocytes Lipidomic Analysis of Adverse Cardio-Cerebrovascular Outcome in Maintenance Hemodialysis Patients

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Qian, Yujun, Peking Union Medical College Hospital, Dongcheng-qu, Beijing, China
  • Zheng, Ke, Peking Union Medical College Hospital, Dongcheng-qu, Beijing, China
  • Li, Xuemei, Peking Union Medical College Hospital, Dongcheng-qu, Beijing, China
Background

Cardio-cerebrovascular diseases are prevalent and devastating in maintenance hemodialysis patients. Lipid metabolism is vital for cardiovascular diseases in non-dialysis population. The disorder of lipid metabolism in dialysis patients is prominent, but the relation of lipids to cardiovascular diseases in dialysis patients is still controversial. Traditional lipids makers failed to identity hemodialysis patients with high risk of cardio-cerebrovascular event. Using high-coverage targeted lipidomic analysis, this study aimed to evaluate the potential of lipids to assess risk of future cardio-cerebrovascular events in hemodialysis patient.

Methods

From July 2013 to August 2019, we followed up the dialysis patients in our dialysis center for stroke and myocardial infarction events, and these patients’ plasma and hemocytes were stored at the baseline. Lipidomic analyses were performed on an Exion LC-system coupled with a QTRAP 6500 PLUS system (Sciex). Principal component analysis and orthogonal project to late structures discriminant analysis, and t-test were used to analyze the differences between patients in with /without adverse cardio-cerebralvascular outcome groups.

Results

A total of 45 plasma samples and 117 hemocytes samples were collected. 9 plasma samples and 28 hemocytes samples were from patients with cardio-cerebrovascular events. 539 kinds of lipid metabolites were detected in plasma, 237 kinds of lipid were detected in erythrocytes. Compared with the patients without cardio-cerebrovascular events, the patients with events presented higher level of plasma PS 34:2 and TAG 44:1 (16:1), lower level of plasma TAG 52:6 (16:2), TAG 58:9 (22:5), LPS 18:0, and lower level of erythrocytes Cer d18:1/20:0, Cer d18:1/18:0 and cerd18:1/21:0 (Fold change >1.5 or <1/1.5, P value <0.05).

Conclusion

These findings revealed novel plasma and erythrocytes lipid predictors for cardio-cerebrovascular diseases in hemodialysis patients.

Funding

  • Clinical Revenue Support